Author Archives: admin


Stem Cell Clinic > Articles by: admin

Nuvilex Reveals Goldman Small Cap Research Cites Groundbreaking Cancer Therapy in Updating Buy Recommendation

By Uncategorized

SILVER SPRING, Md.--(BUSINESS WIRE)--

Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, announced today Goldman Small Cap Research has reissued its buy recommendation on Nuvilex with a short term price target of $0.50 per share.

According to the research report prepared by Goldman, The current share price represents but a fraction of its true value, in our view. With recently increased interest and valuation in the pancreatic cancer treatment arena, we believe that Nuvilex is worth $0.20 just on the oncology therapies alone and that the shares will reach $0.50 in the next six months. Looking ahead, as milestone events occur, $1.00 per share is within reach over the next 12-18 months.

Goldman bases this value projection, in part, on the pending acquisition of SG Austria assets, and with it complete control over the cell encapsulation technology that forms the backbone of Nuvilexs planned biotechnology development. The report states in part the following:

Following execution of the SG Austria asset acquisition, we expect to see a flurry of events and progress on the development side which will serve as catalysts, including when management submits its protocol for the next stage pancreatic cancer trial. We would not be surprised to see the stock break through the $0.50 price on such news as well as progress on the next stage of trials for other therapies.

One reason we are so convinced of the great buying opportunity is the fact that pancreatic cancer treatments are currently at the forefront of the biotech space and are enjoying very high valuations. Although Nuvilex is a not a drug producer, but an existing therapy enhancer through the use of its live cell encapsulation enhancement platform, the timing of these milestone events could not be better for Nuvilex and a re-valuation of its offering.

The Goldman report also compares alternative oncology therapies, including Gemzar from Threshold Pharmaceuticals and Merrimack Pharmaceuticals drug encapsulation technology, noting that, contrary to these treatments, the Nuvilex live-cell encapsulation technology is not limited to one specific use, but can be adapted to use for a host of cell types. The report states, Its difficult to compare apples-to-apples in this space as Nuvilex is the only firm utilizing live-cell encapsulation therapy for cancer, while all the other treatments are based upon a particular drug usage. Contrasting the results of different Phase II clinical trials, the Goldman report comments that the pancreatic cancer therapy, based on completed Phase 1/2 data, appears to have yielded statistically greater results than competing technologies.

Commenting on The Goldman Report, Nuvilex Chief Executive Officer, Dr. Robert Ryan, stated, The report did an excellent job highlighting the value and capabilities of our cell encapsulation technology, not just for cancer therapy, but also for the vast array of treatments where live-cell encapsulation can aid multiple diseases. In the case of the completed cancer trials, it generated superior results with lower drug dosages, and reduced chemotherapeutic side effects. As we move forward with diabetes and stem cell therapy treatments, we are confident our success will, as Goldman predicts prompt leaders in multiple treatment segments to partner with Nuvilex in order to maintain their respective market shares.

Investors are recommended to study the Goldman Research Report for a detailed review and valuation methodology regarding Nuvilex.

About Nuvilex

See the original post here:
Nuvilex Reveals Goldman Small Cap Research Cites Groundbreaking Cancer Therapy in Updating Buy Recommendation

Stem-Cell Therapy Takes Off in Texas

By Stem Cell Treatment

By David Cyranoski of Nature magazine

With Texas pouring millions of dollars into developing adult stem-cell treatments, doctors there are already injecting paying customers with unproven preparations, supplied by an ambitious new company.

The US Food and Drug Administration (FDA) has not approved any such stem-cell treatment for routine clinical use, although it does sanction them for patients enrolled in registered clinical trials. Some advocates of the treatments argue, however, that preparations based on a patient's own cells should not be classed as drugs, and should not therefore fall under the FDA's jurisdiction.

There are certainly plenty of people eager to have the treatments. Texas governor Rick Perry, for instance, has had stem-cell injections to treat a back complaint, and has supported legislation to help create banks to store patients' harvested stem cells.

One company that has benefited from this buoyant climate is Celltex Therapeutics, which "multiplies and banks" stem cells derived from people's abdominal fat, according to chairman and chief executive David Eller. Its facility in Sugar Land, just outside Houston, opened in December 2011 and houses the largest stem-cell bank in the United States.

Celltex was founded by Eller and Stanley Jones, the orthopaedic surgeon who performed Perry's procedure, and it uses technology licensed from RNL Bio in Seoul. Because clinical use of adult-stem-cell treatments are illegal in South Korea, RNL has since 2006 sent more than 10,000 patients to clinics in Japan and China to receive injections.

Celltex says that although it processes and banks cells, it does not carry out stem-cell injections. It declined to answer Nature's questions about whether its cells have been used in patients. But there is evidence that the company is involved in the clinical use of the cells on US soil, which the FDA has viewed as illegal in other cases.

Public hype

In addition to the publicity surrounding Perry's treatment, a woman named Debbie Bertrand has been blogging about her experiences during a five-injection treatment with cells prepared at Celltex. Her blog (http://debbiebertrand.blogspot.com) hosts photographs of herself alongside Jones; Jennifer Novak, a Celltex nurse; Jeong Chan Ra, chief executive of RNL Bio; and her doctor, Jamshid Lotfi, a neurologist who works for the United Neurology clinic in Houston. Another photo is captioned: "My cells are being processed in here for my next infusion!!!" A third shows Bertrand, Lotfi and a physician called Matthew Daneshmand, who is, according to the caption, injecting Bertrand's stem cells into an intravenous drip, ready for the infusion. Nature has been unable to contact Bertrand.

Lotfi says that he has administered cells processed by Celltex to more than 20 people. "Five or six" -- including Bertrand -- have multiple sclerosis and "four or five" have Parkinson's disease, he says. Lotfi explains that patients sign up for treatment by contacting Novak, and that cells are prepared by removing about five grams of fat -- containing roughly 100,000 mesenchymal stem cells -- from the patient's abdomen. Over a three-week period, the cells are cultured until they reach about 800 million cells. Lotfi says that patients get at least three injections of 200 million cells each, and that the cells do not take effect for a few months. According to Lotfi, Celltex charges US$7,000 per 200 million cells, and pays Lotfi $500 per injection.

See the article here:
Stem-Cell Therapy Takes Off in Texas

Why This Top Supplement Stacks Up

By Stem Cell Medical Center

(PRWEB) February 29, 2012

Stem Cell Worx has brought a much needed new breakthrough health supplement to market. Not only does this top supplement activate adult stem cells naturally, it is also delivered sublingually.

Combine these two powerful forces and you get a new age, natural health supplement that aligns with todays science.

CEO and Co-founder, Tony Sampson explains: Emerging science has enabled incredible medical breakthroughs to be made, particularly in the last 5 years. Now it's time for these breakthroughs to correlate into health and nutritional supplements. This is what has been achieved with the Stem Cell Worx Intraoral Spray.

"It is now acknowledged worldwide that adult stem cells are the bodys primary system of renewal and restoration. However, with age, the release rate of one's own adult stem cells from the bone marrow decreases significantly, leaving us more prone to aging, illness and disease. Therefore, it is extremely important one's own adult stems continue to be activated throughout each individual's life time, no matter what their age.

Adult stem cells are behind practically every success of stem cell treatment and therapies thus far, not embryonic stem cells. Our own adult stem cells are the future of our good health. They are the only known source for rebuilding the body and renewing health by restoring lost or degraded cells.

The key ingredients in the Stem Cell Worx Intraoral Spray are scientifically proven to activate our adult stem cells, strengthen our immune system and provide optimal support for the bodys own repair and renewal system. Having healthy stem cells and a strong immune system are the very essence of life and good health.

Adult stem cells, once in the blood stream, have the ability to seek out areas within the body where they are needed the most. They then migrate to those areas and start the repair and renewal process.

Ask Stem Cell Worx CEO and Co-Founder, Tony Sampson why and he explains, Our formulation is made from the highest grade of natural ingredients in the world and our delivery system of these nutrients is direct and unique compared to main stream applications like tablets and capsules. Spray this dietary supplement under the tongue, hold then swallow.

"It is scientifically proven and referenced that a sublingual delivery method enables 95% of all nutrients to be absorbed directly into the blood stream through the sub-mucosal membrane (that sits directly under the tongue) compared to just 10% - 20% absorption that tablets and capsules provide. "Most people dont know this and many Health Professionals and Health Companies dont want to acknowledge it," states Tony Sampson, Stem Cell Worx CEO and Co-Founder.

Read the original here:
Why This Top Supplement Stacks Up

IU doctors land large grant for adult stem cell research

By Stem Cell Clinic

INDIANAPOLIS -

An announcement involving cutting edge research of adult stem cells has doctors at Indiana University excited.

The doctors have been included in a $63 million National Institutes of Health project nabbing spots the Cleveland Clinic and Vanderbilt lost and patients here will benefit from.

Dr. Mike Murphy and Dr. Keith March will head up the IU effort, one of seven nationwide sites just named to recruit 500 patients over the next seven years who have heart attacks, heart failure or poor circulation in the legs for adult stem cell research.

"What we are doing is taking the cells from one part of the body and bringing them to another area that needs repair more urgently,' said March. "They are able to repair a variety of tissues by either decreasing inflammation by helping tissues not to die if they are at risk of death, or by helping them even to grow and regenerate."

The new NIH Cardiovascular Cell Therapy Research Network distinction follows years of work with patients like Ruth Diggs, who was diagnosed with peripheral arterial disease in New York.

"They were just telling me the only solution for me was to amputate the leg," Diggs said.

Unhappy with that option, Ruth traveled to Indiana and enrolled in a clinical trial at IU, where adult stem cells were injected in to her leg. That led to regeneration and Ruth's leg was saved.

"The fact that she has her leg, we are very, very grateful," said Ruth's daughter, Melvina Jagack.

Murphy showed images of blood flow through the leg of a male patient from Maine who enrolled in the clinical trial.

Visit link:
IU doctors land large grant for adult stem cell research

Cryo-Save Carries on its Stem Cell Education Program in Bulgaria

By Stem Cell Clinic

ZUTPHEN, The Netherlands, February 29, 2012 /PRNewswire/ --

Cryo-Save Bulgaria participated in the 5th National Conference of Obstetricians & Gynecologists from the Out-patient Setting, held on February 24-26 in Plovdiv, Bulgaria.

After the recent initiatives in Italy, Serbia and Bosnia, Cryo-Save Bulgaria joins Cryo-Saves official training plans and reaffirms the efforts of the company to put together its educational program about stem cells therapies and current applications.

Cryo-Save Bulgaria gave a presentation about why the stem cells from the umbilical cord blood should be donated or saved, and not wasted. Topics that have been covered include the advances and perspectives on stem cell therapies, the regulatory issues of the physician and his responsibility to inform the patient, and the different services offered by Cryo-Save to the patients.

Dr. Mandov, from Vesela Maternity Clinic, Plovdiv, said: "In the last couple of years, there was an ever growing interest in cryo-preservation of stem cells among pregnant women. We welcome Cryo-Saves initiative to be pro-active in educating obstetricians about this topic, so that we can convince patients more effectively about the potential benefits of stem cell storage."

The conference has been organized by the National Society of Obstetricians/Gynecologists from the Ambulatory Care.

Dr. Petrov, Chief Organizer of the event and Chairman of the Bulgarian Society of Obstetricians & Gynecologists in the Out-patient Setting, said: "Stem cell based therapies and regenerative medicine represent one of the most promising development avenues for modern medicine to go. We appreciate Cryo-Saves participation in this event because it gave us some up-to-date insight into cryo-preservation and clinical application of cord blood derived stem cells. We also highly appreciate Cryo-Saves "Donate or Save" initiative because of its clear public health benefit potential."

Because of its leading role in the stem cell storage industry, Cryo-Save has developed multiple educational programs aimed at increasing global awareness about current treatments and future promising applications. The company is convinced that everyone should be aware of the options available to them and have the opportunity to store their babys stem cells.

Cryo-Save: http://www.cryo-save.com/group

Cryo-Save, the leading international family stem cell bank, stores more than 200,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on four continents, with ultra-modern processing and storage facilities in the United States, Belgium, Germany, Dubai, India, South Africa and France (validation in progress).

Excerpt from:
Cryo-Save Carries on its Stem Cell Education Program in Bulgaria

International Cellular Medicine Society Grants First Worldwide Accreditation to Tijuana Clinical Trial

By Uncategorized

Regenerative Medicine Institute, Mexico has been granted full accreditation for its clinical stem cell trials

Portland, Oregon (PRWEB) February 29, 2012

We are pleased that RMI undertook this process, says David Audley, executive director of the ICMS. The clinic understood that patient safety can only be assured through strict evaluation and rigorous oversight. From day one they have embraced the transparency that this program requires.

RMI is the first clinic to achieve this status under the ICMS Accreditation Program. The clinic has undergone two separate site audits as well as an institutional review board review evaluation. Most importantly, the clinic has placed in excess of 50 patients into the Treatment Registry for long-term outcome tracking. The safety profile has been excellent, continued Audley. We have tracked patients over at least two follow-ups and a minimum of six months and not seen a single cell-related adverse event.

The ICMS is currently evaluating nearly a dozen clinics worldwide. Accreditation is based upon the Guidelines for the Practice of Cell-Based Medicine developed and published by the ICMS. Key components of these guidelines are the ethical recruitment of patients, proper consent of patients and compliance with local laws and regulations in the treatment of patients.

###

Mr. David Audley International Cellular Medicine Society 503-884-6590 Email Information

View original post here:
International Cellular Medicine Society Grants First Worldwide Accreditation to Tijuana Clinical Trial

Program looks at stem-cell therapy to defeat aging

By Uncategorized

Allegheny-Kiski Health Foundation will present "Stem-Cell Therapy: Defeating the Aging Process" from 6 to 8 p.m. March 13 in the William & Grayce Walker conference Room at Allegheny-Kiski Health Foundation, Charles and Mary Lou Young Non-Profit Center, 1 Acee Drive, Natrona Heights.

Guest speaker will be Dr. Valerie Donaldson of the Individualized Advanced Medical Center of Pittsburgh. She is active in destressing the body and focusing on the anti-aging process.

Donaldson completed her undergraduate education at Colorado College where she earned a bachelor's degree in biology and obtained her doctorate at Rush Medical College in Chicago.

Registration is requested. Call 724-294-3157. Admission is free.

The seminar is sponsored through the Dr. H.W. Fraley Health and Wellness Fund.

Programs set at Destination Wellness

Upcoming programs at Allegheny Valley Hospital's Destination Wellness at Pittsburgh Mills, Frazer, include:

Pittsburgh North Restless Legs Syndrome Support Group will meet from 6:15 to 7:45 p.m. Dr. Avinash Aggarwal will discuss "Is it RLS or Something Else?" To register, call Destination Wellness at 724-274-5202.

Heartsaver First Aid, part one will be from 9 a.m. to noon March 10 and is the basic first-aid course. A two-year certification card will be given after completion of skills and written testing. Fee is $35 per part and includes a required student manual. Call 724-274-5202 to register. Space is limited to eight participants.

Heartsaver AED/CPR, part two will be from 1 to 4 p.m. March 10 and includes adult, child and infant CPR and automated external defibrillator use. A two-year certification card will be given after completion of skills and written testing. Fee is $35 per part and includes required student manual. Call 724-274-5202 to register. Space is limited to eight participants.

Visit link:
Program looks at stem-cell therapy to defeat aging

Diverse approach to cancer research need of the hour, stresses professor

By Uncategorized

Diverse approach to cancer research need of the hour, stresses professor Profoundly different approaches are needed for cancer research, the Qatar International Conference on Stem Cell Science and Policy 2012, has been told by an expert in cancer stem cell (CSC) biology.
Professor Irving Weissman, director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, was delivering a keynote address on ‘Normal and neoplastic stem cells’ yesterday.
“Self-renewal is the principal property that distinguishes stem cells from their daughter cells,” he said while explaining that when stem cells divide they give rise to stem cells (by self-renewal) and progenitors (by differentiation).
The balance between self-renewal and differentiation is what generates, and then maintains, tissues enabling them to respond to injury or other stressors.
Studies identifying hematopoietic stem cells (HSC) - which form blood and immune cells - and progenitors, have made hematopoiesis one of the best systems for studying the molecular changes in cell fate decision-making and creation of cancer.
Further, it serves as a paradigm for finding preclinical and clinical platforms for tissue and organ replacement and regeneration.
Stem cell isolation and transplantation is the basis for regenerative medicine. Self-renewal is dangerous and therefore strictly regulated.
Poorly regulated self-renewal can lead to the genesis of CSC — the only cells within a tumour or leukaemia that have the ability to self renew, and therefore the cells that maintain the cancer.
“Thus, it is predicted that CSC elimination is required for cure. This prediction necessitates profoundly different approaches to cancer research, compelling investigators to prospectively isolate CSCs and to characterise the molecular pathways regulating their behaviour in order to identify targeted and truly effective therapies,” Weissman added.
A founder of three companies – SyStemix, Cellerant, and Stem Cells Inc – all focused on bringing stem cell therapies into the clinic, Weissman has authored more than 700 scientific articles and has been an editor of multiple scientific journals.

Go here to read the rest:
Diverse approach to cancer research need of the hour, stresses professor

Stem Cell Therapy Book ~ Enhance Your Stem Cells – Video

By Uncategorized

28-02-2012 12:18 FREE STEM CELL BOOK! myjdimlm.com PUBLIC SERVICE VIDEO Home of JDI Multi Vitamin-Minerals with Stem Cell Nutrition Support Overcome the Aging Process. As we age, the body releases fewer and fewer adult stem cells which are the body's rebuilding tools. Stem cell nutrition helps overcome the aging process by promoting the release of additional adult stem cells in the body. This book contains over 70 different stories from doctors, everyday people, and even about how stem cell nutrition helps animals. Get this book FREE with your first purchase or when you become an active auto-ship member. Join us TODAY and start the Journey that will set you FREE!!! http Enhance your Stem Cells with JDI MultiVitamin with Stem Cell Nutrition Support utilizing... Vita-Stim™ Stem Cell Nutrition Vita-Stim is an all-natural patented supplement that helps to increase the release of adult stem cells or what are also known as progenitor cells noted below. It is not to be confused with any other product that has less than 750 mg. of active ingredient per capsule and could consist of merely fruit extracts and/or simply Aphanizomenon flos-aquae (AFA) extracts.

Read more here:
Stem Cell Therapy Book ~ Enhance Your Stem Cells - Video

Baxter Begins Phase III Adult Stem Cell Trial For Chronic Cardiac Condition

By Stem Cell Treatment

(RTTNews.com) - Baxter International Inc. (BAX) said it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia.

Chronic myocardial ischemia is one of the most severe forms of coronary artery disease, causing significant long-term damage to the heart muscle and disability to the patient.

The company said that the trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three arms, namely treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care. The primary objective is to evaluate the efficacy of treatment with CD34+ stem cells to improve the functional capacity of patients with chronic myocardial ischemia, as measured by a change in total exercise capacity at 12 months following treatment.

Efficacy will be measured by a change in total exercise capacity during the first year following treatment and safety data will be collected for two years.

The company noted that the trial is being initiated based on the phase II data, which indicated that injections of patients' own CD34+ stem cells may improve exercise capacity and reduce reports of angina episodes in patients with chronic, severe refractory angina.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Read the rest here:
Baxter Begins Phase III Adult Stem Cell Trial For Chronic Cardiac Condition

→←